ReviewSkin health and disease2025
The case for etanercept in the management of toxic epidermal necrolysis.
Review in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxic epidermal necrolysis (TEN) is a dermatological emergency with devastating morbidity and mortality rates. It is most often caused by medications. Management guidelines have focused on conservative measures, partly due to a previous lack of large randomized controlled trials evaluating systemic agents, and because experts have differing views on initiating active medical management. Tumour necrosis factor alpha (TNF-α) is a cytokine that is involved in immune defence against various infectious agents by exerting a powerful anti-inflammatory effect. Inhibition of TNF-α is well established in the management of noninfectious inflammatory (including dermatological) conditions. Patients with TEN have prominent expression of TNF-α in keratinocytes and macrophages in affected skin as well as in blister fluid. This review article aims to summarize the recent and emerging evidence for using anti-TNF-α treatment, particularly etanercept, in the management of TEN.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.